Welcome to our dedicated page for Outlook Therapeutics news (Ticker: OTLK), a resource for investors and traders seeking the latest updates and insights on Outlook Therapeutics stock.
Outlook Therapeutics, Inc. develops and commercializes ONS-5010/LYTENAVA, an ophthalmic formulation of bevacizumab for retina diseases, including wet age-related macular degeneration. Company news commonly covers the product’s European Commission and MHRA marketing authorizations, commercial launch activity in Germany, Austria and the UK, and U.S. regulatory communications involving the biologics license application pathway for neovascular AMD.
Updates also include capital-structure actions used to fund operations, such as public offerings, registered direct offerings, warrants, convertible-note amendments and note financing. Governance and shareholder-approval matters appear in connection with securities issuance and authorized-share requirements.
Outlook Therapeutics (Nasdaq: OTLK) appointed Kevin Lundquist as Chief Financial Officer, effective September 1, 2026, as it builds financial and operational infrastructure for the planned U.S. commercial launch of LYTENAVA™ following its FDA approval for wet age-related macular degeneration (wet AMD).
Lundquist brings more than 20 years of corporate finance and capital markets experience across pharmaceutical, biotechnology, medical technology, and manufacturing businesses, including IPO support, SEC reporting, capital raising, M&A, and commercial operations leadership. He previously held senior roles at CapsoVision, Abzena Biologics, Revance Therapeutics, Genentech/Roche, Caterpillar Japan, and Abbott Laboratories.
Lawrence Kenyon will step down as CFO on September 1, 2026 and remain as a non-executive employee through September 30, 2026. Outlook Therapeutics also approved an inducement stock option grant for Lundquist covering 500,000 shares, vesting over four years.
Outlook Therapeutics (Nasdaq: OTLK) announced that CEO Bob Jahr participated in the Virtual Investor “Why Now” on-demand conference. The segment focuses on the company’s transition after FDA approval of LYTENAVA™ (bevacizumab-vikg) for wet age-related macular degeneration (wet AMD) in the U.S. on July 24, 2026.
According to Outlook Therapeutics, Jahr discussed moving from a development-stage to a commercial-stage company, U.S. launch preparations, the company’s existing commercial presence in Europe, and the opportunity for an FDA-approved ophthalmic bevacizumab in a market where bevacizumab is widely used off label. The webcast is now available for on-demand viewing.
Outlook Therapeutics (Nasdaq: OTLK) reported third quarter fiscal 2026 results and highlighted FDA approval of LYTENAVA™ (bevacizumab-vikg), the only FDA‑approved ophthalmic bevacizumab for treating wet age‑related macular degeneration (wet AMD) in the U.S. The company is preparing a U.S. launch before the end of calendar 2026, including payer engagement, commercial supply scaling, and a planned HCPCS reimbursement code application by October 1, 2026.
For the quarter ended June 30, 2026, OTLK posted a net loss attributable to common stockholders of $20.3 million, or ($0.15) per share, versus a $20.2 million loss, or ($0.55) per share, a year earlier. Adjusted net loss improved to $10.9 million from $15.8 million. Revenue declined to $9,000 from $1.5 million, with negative gross profit. Cash and cash equivalents were $11.2 million at quarter‑end.
Subsequent to quarter close, Outlook Therapeutics completed a public offering of 55,555,556 shares and accompanying warrants, generating approximately $51.1 million in net proceeds. Commercialization of LYTENAVA is underway in Germany, Austria and the UK, with launches planned in the Netherlands in 2026 and Switzerland in 2027 via partner Mediconsult.
Outlook Therapeutics (Nasdaq: OTLK) priced an underwritten public offering of 55,555,556 shares of common stock and accompanying warrants to purchase up to 55,555,556 shares. The combined public offering price per share and warrant is $0.99, with warrants exercisable immediately at $1.10 and expiring five years after issuance.
Underwriters have a 30-day option to buy up to 8,333,333 additional shares and/or warrants. Gross proceeds are expected to be about $55.0 million before fees, with closing expected on August 14, 2026. According to Outlook Therapeutics, net proceeds will support the planned U.S. commercial launch of LYTENAVA and general corporate purposes.
Outlook Therapeutics (Nasdaq: OTLK) has commenced an underwritten public offering of common stock and accompanying warrants to purchase common shares. All securities in the proposed deal will be sold by the company, with Piper Sandler and BTIG acting as joint bookrunning managers.
Outlook Therapeutics expects to grant underwriters a 30-day option to buy up to 15% additional shares and/or warrants on the same terms. Net proceeds, together with existing cash, are intended to fund the planned U.S. commercial launch of LYTENAVA for retinal diseases, and for working capital and general corporate purposes.
Outlook Therapeutics (Nasdaq: OTLK) will report its third quarter fiscal year 2026 financial results and host a corporate update conference call and webcast on Friday, August 14, 2026, at 8:30 AM ET. The call will be led by CEO Bob Jahr and EVP/CFO Lawrence A. Kenyon. Domestic participants can dial 877-407-8291, international participants can dial +1 201-689-8345, referencing the Outlook Therapeutics conference call. A live webcast and 90-day archive will be available on the Events page in the Investor section of the company’s website, outlooktherapeutics.com.
Outlook Therapeutics (Nasdaq: OTLK) announced U.S. FDA approval of LYTENAVA™ (bevacizumab-vikg) as the first and only FDA-approved ophthalmic bevacizumab for treating neovascular age-related macular degeneration (wet AMD) in the United States. The ophthalmic formulation is developed specifically for intravitreal use in the eye and is supported by clinical evidence, validated manufacturing, approved labeling, and ongoing FDA oversight.
According to Outlook Therapeutics, the company anticipates 12 years of Reference Product Exclusivity under the BPCIA and is executing a U.S. commercial launch targeting the approximately $8.5 billion anti-VEGF retina market. LYTENAVA is expected to be available to eligible U.S. patients before year-end, with reimbursement and patient-assistance programs to support access. The product already holds marketing authorizations in the EU and UK for wet AMD.
Outlook Therapeutics (Nasdaq: OTLK) announced FDA acceptance of its resubmitted Biologics License Application for ONS-5010/LYTENAVA™ (bevacizumab-vikg) to treat neovascular age-related macular degeneration (wet AMD).
The resubmission is under a Class 1 review with a Prescription Drug User Fee Act (PDUFA) target action date of July 29, 2026. Outlook Therapeutics has begun pre-launch activities while the FDA review proceeds.
Outlook Therapeutics (Nasdaq: OTLK) resubmitted its Biologics License Application to the U.S. FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg) to treat neovascular age-related macular degeneration (nAMD). The FDA Office of New Drugs concluded substantial evidence of effectiveness and indicated no additional trials are required.
The resubmission is designated a Class 1 review, with a PDUFA decision expected within 60 days of FDA receipt, and interactions now focusing on final product labeling.
Outlook Therapeutics (Nasdaq: OTLK) priced a registered direct offering of 8,539,709 common shares at $0.5855 per share, to largest stockholder GMS Ventures and Investments, for expected gross proceeds of $5.0 million.
Closing is expected around May 29, 2026. Warrants for up to 15,488,570 shares will have their exercise price reduced to $0.5855 per share, effective at closing. Net proceeds will support working capital and general corporate purposes.